جست‌وجوی استاد و پژوهشگر

Marios Georgakisمشاهده پروفایل

پژوهشگر

• Cardiovascular Disease
• Stroke
• Atherosclerosis
• +۸ مورد دیگر

Marios Georgakis is a clinician-scientist and Junior Group Leader at the Institute for Stroke and Dementia Research (ISD) at LMU Munich. He also holds a Visiting Scientist position at the Broad Institute of MIT and Harvard. His research focuses on leveraging multi-omics data and causal inference methods (e.g., Mendelian randomization) to discover drug targets for atherosclerosis, develop personalized risk stratification tools for cerebrovascular disease, and identify in vivo biomarkers of disease activity. His work bridges human genetics, molecular biology, and clinical translation. Education : MD and PhD (Epidemiology) from the National and Kapodistrian University of Athens; doctoral studies in Systemic Neurosciences at LMU Munich. Honors : Emmy Noether Award (DFG), CHARGE Consortium Early Career Achievement Award, Hertie Network Fellowship, and multiple scholarships/fellowships. Research Themes : Drug target discovery for cardiovascular disease via multiomics integration Molecular phenotyping of atherosclerosis using single-cell RNA-seq and spatial transcriptomics Development of AI-driven tools for vascular imaging and aging Genetic studies of inflammation, cytokines, and stroke subtypes Causal inference in vascular risk prediction and post-stroke outcomes Recent Article Trends : His team's publications (2024-2020) emphasize: Proteogenomic and genetic studies of atherosclerosis Cytokine signaling pathways (e.g., IL-6, CCL2/CCR2) Polygenic and genomic risk scores for stroke Multi-omics biomarkers in cerebrovascular disease Clinical translation of Mendelian randomization findings Meta-analyses of population-based data Scientific Awards : Emmy Noether Group Leader Award (DFG, 2023) CHARGE Consortium Early Career Achievement (2023) Hertie Network Fellowship (2023) Walter-Benjamin Postdoctoral Fellowship (2021-2022) Team Leadership : Georgakis mentors multiple PhD students and postdocs in his lab. His group collaborates with vascular surgeons, neurologists, and computational biologists. Current projects include the AtherOMICS biobank and AI-driven vascular phenotyping tools.

Marios Georgakisمشاهده پروفایل

پژوهشگر

• Biomedical Neuroscience
• Cerebrovascular Disease
• Stroke
• +۷ مورد دیگر

Dr. Marios Georgakis is a Clinician-Scientist and Junior Group Leader at the Institute for Stroke and Dementia Research (ISD) at Ludwig-Maximilians-Universität München (LMU Munich). He also serves as a Visiting Scientist at the Broad Institute of MIT and Harvard and is completing his clinical residency in Neurology at LMU University Hospital. As Principal Investigator of the Georgakis Lab, he leads a research team focused on developing precision medicine approaches for cerebrovascular diseases. Education: Medical studies (M.D.): Medical School, National and Kapodistrian University of Athens, Greece (2009-2015) Master studies (M.Sc.): Molecular Physiology (Neurosciences), National and Kapodistrian University of Athens, Greece (2015-2017) Doctoral studies (D.Sc.) in Epidemiology, National and Kapodistrian University of Athens, Greece (2015-2019) Doctoral studies (Ph.D.) in Graduate School of Systemic Neurosciences (GSN), LMU Munich, Germany (2017-2020) Dr. Georgakis' research focuses on leveraging big data from epidemiological studies and human biobanks to develop precise and personalized preventive and therapeutic strategies for cerebrovascular diseases. His work spans biomedical neuroscience with particular emphasis on cerebrovascular disease, stroke, atherosclerosis, cerebral small vessel disease, multi-omics, data science, epidemiology, and population genetics. He employs innovative bioinformatic tools including genome-wide association studies, Mendelian randomization, multi-omics integration, single-cell transcriptomics, spatial transcriptomics, and machine learning to discover causal mechanisms, identify therapeutic targets, develop risk stratification tools, and create accurate biomarkers for cerebrovascular diseases. His laboratory has established the AtherOMICS biobank for human atherosclerotic plaque samples and developed computational pipelines for big data analyses. Recent publication trends show a strong focus on genetic architecture of stroke, inflammatory pathways in cerebrovascular disease, and development of polygenic risk scores for clinical application. Scientific Awards: Emmy Noether Independent Group Leader Award, German Research Foundation (DFG), 2023 Early Career Achievement Award, CHARGE Consortium, 2023 Fellow of the Hertie Network of Excellence in Clinical Neuroscience, 2023 Clinician-Scientist Fellow of the Excellence Munich Cluster for Systems Neurology (SyNergy), 2023 Walter-Benjamin Fellowship for postdoctoral research by German Research Foundation (DFG), 2021-2022 Dr. Georgakis actively mentors a diverse team of 12 current students and postdocs including PhD students, MD students, and clinician scientists, with several alumni who have completed their training in his lab. His research is supported by multiple grants including the Emmy Noether program from the German Research Foundation, focusing on multi-omics characterization of immune mechanisms driving human atheroprogression, dissecting cerebrovascular atherosclerosis with population genetics, and developing personalized biomarkers using deep learning. The Georgakis Lab operates two main research platforms: the AtherOMICS Biobank for human atherosclerotic plaque samples and the Big Data Lab for computational analyses. These platforms enable his team to conduct deep phenotyping of human atherosclerosis, develop in vivo diagnostics, discover therapeutic targets, and create personalized diagnostic and risk prediction tools for cardiovascular diseases.

Mathias Munschauerمشاهده پروفایل

پژوهشگر

• Molecular Virology
• RNA Biology
• Host-Pathogen Interactions
• +۷ مورد دیگر

Mathias Munschauer leads the Department of Molecular Virology at Heidelberg University's Faculty of Medicine, within the Center for Infectious Diseases. His research group focuses on unraveling RNA regulatory mechanisms that govern viral infection outcomes, with emphasis on HCV, HBV, and Dengue virus. His research interests lie at the intersection of RNA biology and virology, particularly in understanding how viral RNA molecules interact with host cell components. The lab employs cutting-edge methodologies including RAP-MS and SHIFTR for RNA interactomics, integrated with functional genomics, single-cell transcriptomics, and AI-driven analysis of high-dimensional data. This systems-level approach enables the identification of host factors and regulatory pathways critical for viral replication and immune evasion. The recent publications highlight a strong trend toward spatially and temporally resolved analysis of RNA-protein interactions across diverse RNA viruses. There is a consistent focus on developing and applying innovative technologies to map host-virus interfaces, with applications in identifying antiviral targets and understanding infection mechanisms. The work spans molecular, cellular, and systems biology, with increasing integration of computational and machine learning approaches. Systems virology RNA-protein interactomics Host-pathogen interactions CRISPR screening Single-cell analysis Antiviral strategies Dr. Munschauer mentors a research team and contributes to the doctoral program in Infectious Diseases. His lab develops and shares novel reagents and methods, fostering collaborative science. While specific grants are not listed, the technological sophistication suggests substantial funding support. The lab operates within a vibrant research environment alongside other virology groups such as AG Bartenschlager and AG Ruggieri. The Munschauer Lab is part of a larger virology and infectious disease research ecosystem at Heidelberg University, collaborating across disciplines to advance understanding of viral pathogenesis. The team actively develops and applies innovative tools for RNA-centric discovery, positioning the group at the forefront of molecular virology.

David M. Langenauمشاهده پروفایل

استاد

• Pediatric Oncology
• Cancer Biology
• Zebrafish Models
• +۳ مورد دیگر

David M. Langenau is a Professor of Pathology at Harvard Medical School and Director of Research Education at Mass General Brigham Pathology . His work focuses on elucidating molecular mechanisms of relapse in pediatric sarcomas and leukemias using zebrafish models, human cell lines, and patient-derived xenografts. Institutional Affiliations : Harvard Medical School, Mass General Brigham, Krantz Family Center for Cancer Research, Harvard Stem Cell Institute Research Themes : Tumor relapse biology, cancer stem cells, oncogenic pathways, zebrafish avatars, drug discovery Langenau's research has identified novel combination therapies (e.g., Olaparib-Temozolomide for RMS) and uncovered evolutionarily conserved oncogenic drivers in T-ALL. His team's work bridges zebrafish genetics and clinical translation, including the first zebrafish-origin clinical trial for pediatric cancer. Selected Research Trends : Recent publications highlight single-cell transcriptomics in RMS, checkpoint pathways in immunotherapy, and PI3K-AKT-mTOR signaling in T-ALL. These studies integrate bioinformatics, functional assays, and clinical data. Grants and Collaborations : His laboratory receives over $19 million annually in research funding and collaborates with institutions like Dana-Farber Cancer Institute and MGH Pathology Service .

Zhang Yangمشاهده پروفایل

دانشیار

• Artificial Intelligence in Biomedical Imaging
• Deep Learning for Omics Data Analysis
• Pathogen Detection and Diagnostics
• +۷ مورد دیگر

Zhang Yang is an Associate Professor at the School of Medical Engineering, Harbin Institute of Technology (Shenzhen), with a joint appointment as Visiting Professor at the University of Tokyo starting in July 2024. He holds a PhD from the University of Cambridge's Department of Pathology and an M.Phil. from the University of Hong Kong's HKU-Pasteur Research Center. Previously, he served as an Assistant Professor at Harbin Institute of Technology (Shenzhen) from September 2015 to December 2020. His research integrates computational and experimental approaches to address challenges in pathogen and cancer research. On the computational side, his work focuses on developing AI-powered microscopic imaging systems, applying deep learning to analyze multi-omics data (including proteins, DNA, miRNAs, LncRNAs, and mRNAs), and utilizing deep learning in cheminformatics for drug discovery. On the experimental side, his laboratory combines imaging, high-throughput sequencing, mass spectrometry, and chemical biology to understand disease mechanisms at the molecular level. His publication record demonstrates significant impact, with over 50 SCI-indexed papers in high-impact journals including Nature Communications, Briefings in Bioinformatics, Bioinformatics, Analytical Chemistry, and Trends in Biotechnology. His work has been cited by prestigious journals such as Nature Reviews Methods Primers and Nature Communications, with three ESI highly cited papers. His research spans multiple interdisciplinary fields, combining artificial intelligence with biomedical applications to advance diagnostic and therapeutic approaches. World's Top 2% Scientists 2021 Fellow of the Royal Society of Biology Three ESI Highly Cited Papers Five authorized national invention patents As an academic leader, he serves as Associate Editor for BMC Biology and Frontiers in Microbiology, Academic Editor for PLOS Genetics, Editorial Board Member for Communications Biology, and Guest Editor for a Special Issue on AI in analytical chemistry in Trends in Analytical Chemistry. His laboratory actively collaborates with international institutions, with graduates pursuing further studies at Hong Kong Chinese University, Hong Kong University of Science and Technology, Hong Kong Polytechnic University, Macau University, and the University of New South Wales. He teaches Introduction to Modern Biology for undergraduates and Bioanalytical Chemistry for graduate students.

Hannah Spitzerمشاهده پروفایل

استادیار

• Computational Biology
• Machine Learning
• Spatial Omics
• +۴ مورد دیگر

Hannah Spitzer is a Research Group Leader at the Institute for Stroke and Dementia Research (ISD) at Ludwig Maximilian University of Munich and an associated Research Group Leader at Helmholtz Munich's Computational Health Center. She leads the Spitzer Lab, focusing on computational analysis of multimodal brain datasets to advance understanding of neurovascular and neurodegenerative diseases. Her educational background includes: PhD in Computer Science from Heinrich-Heine University Düsseldorf and Research Center Jülich (2015-2020) Master's in Computer Science from RWTH Aachen (2013-2015) Bachelor's in Computer Science from RWTH Aachen (2009-2013) Dr. Spitzer's research integrates computational biology and machine learning to decode brain complexity, with emphasis on spatial omics analysis , interpretable image representation learning , and cross-modal data integration . Her group develops tools like squidpy and campa for spatial omics while applying graph neural networks to epilepsy lesion detection through the international MELD project, prioritizing biological interpretability in AI models. Recent publications reveal strong trends in leveraging graph neural networks for subtle brain lesion detection and creating computational frameworks for spatial omics integration. Her work consistently bridges advanced machine learning with clinical neuroscience to uncover disease mechanisms in neurodegeneration and vascular disorders. Dr. Spitzer actively mentors students including current PhD candidate Beatrice Guastella and alumni Deniz Fettahoglu (MSc) and Katia Berr (PhD). Her lab operates through major collaborations including the MELD epilepsy consortium and Helmholtz Imaging Project, with funding supporting computational pipeline development for small-vessel disease prediction and multimodal brain atlasing. The Spitzer Lab comprises postdoc Wasim Aftab and PhD student Beatrice Guastella, working on computational pipelines that integrate histology, spatial omics, and neuroimaging data to decode brain disease mechanisms through interpretable AI approaches.

Jochen A. Müllerمشاهده پروفایل

پژوهشگر

• Microbial Transformations
• Environmental Biotechnology
• Molecular Biology
• +۴ مورد دیگر

Jochen A. Müller is a Senior Scientist at the Helmholtz Centre for Environmental Research - UFZ in Leipzig, Germany, within the Department of Molecular Environmental Biotechnology . His research focuses on microbial transformations of organic pollutants, particularly using molecular tools to quantify biocatalysts and analyze microbial roles in contaminated systems. He previously held academic positions at Morgan State University and conducted postdoctoral research at Stanford University and the University of Maryland. Education: Diploma in Microbiology (1996), University of Konstanz Ph.D. in Microbiology (2000), University of Konstanz His research interests span environmental biotechnology, microbial ecology, and genomics, with emphasis on anaerobic degradation of chlorinated ethenes, aromatic compounds, and sulfur-metabolizing microbes. His publications (2012–2023) explore antibiotic resistance gene dynamics, toluene degradation pathways, constructed wetland systems, and innovative single-cell genomics techniques like scMAR-Seq. Professional service includes editorial board membership for Applied and Environmental Microbiology and Saline Systems since 2009. He has contributed to funded projects such as Genomics of Beggiatoa alba (NSF, JGI/DOE) and participated in interdisciplinary collaborations across environmental engineering, biotechnology, and bioeconomy. For contact , he is affiliated with the UFZ in Leipzig. Detailed institutional affiliations and further information can be found in the full description below.

• Bioengineering
• Microfluidics
• Organ-on-Chip Technology
• +۵ مورد دیگر

Matthias Meier is a Full Professor at the Institute of Biochemistry, University of Leipzig, and Principal Investigator at Helmholtz Pioneer Campus, Helmholtz Zentrum München. His research focuses on advancing microfluidic organ-on-chip technology for single-cell and whole-organ disease modeling. Education: PhD in Biophysics (University of Basel, 2006) Research Interests: Dr. Meier's work bridges bioengineering and metabolic disorders, using organ-on-chip platforms to study stem cell differentiation, pancreatic/adipose tissue interactions, and dynamic microenvironmental signals. His lab integrates microfluidics with hiPSC-derived organoids for obesity and diabetes research. Publication Trends: Recent studies emphasize organ-on-chip systems, single-cell analysis , and stem cell engineering , with applications in cardiovascular disease modeling, spatial transcriptomics, and bioelectronic monitoring. Scientific Awards: Feodor-Lynen Postdoctoral Fellowship (2008) Emmy-Noether Fellowship (2012-2018) ERC Consolidator Grant (2017) Advising & Grants: He has led independent research groups with major grants, focusing on energy imbalance mechanisms and patient-specific organoid models for metabolic disease therapies. Labs & Teams: The Matthias Meier Lab develops microfluidic platforms to control chemical, architectural, and mechanical cues for hiPSC differentiation, emphasizing spatial protein profiling and organoid assembly.

Birgit Kemmerlingمشاهده پروفایل

پژوهشگر

• Plant Molecular Biology
• Plant Pathology
• Immunology
• +۵ مورد دیگر

Dr. Birgit Kemmerling is a research group leader at the Center for Plant Molecular Biology (ZMBP) within the Faculty of Science at the University of Tübingen, Germany. Her research focuses on molecular mechanisms of plant innate immunity, particularly the role of leucine-rich repeat receptor-like kinases (LRR-RLKs) in pathogen recognition and defense signaling. Key projects include studying BAK1 and BIR3 kinases involved in immune receptor complex formation and regulation. She collaborates with institutions worldwide and has secured funding from DFG and EU programs such as AFGN, Bravissimo, and SFB1101. Teaching responsibilities include lectures and seminars on comparative immunity in plants and animals, practical courses in molecular mechanisms of innate immunity, and supervision of bachelor/master theses. Her group actively engages in interdisciplinary projects, integrating nanotechnology studies to assess immune responses to nanoparticles across species. Notable collaborators include Prof. Thomas Boller (Basel), Cyril Zipfel (Norwich), and Frans Tax (Tucson). Research highlights include discovering BAK1's dual role in brassinosteroid signaling and immune response regulation, as well as identifying novel LRR-RLK genes activated by pathogen infection. Current work explores nanomaterial biocompatibility and immune system interactions, leveraging advanced microscopy techniques like super-resolution imaging (OneFlowTraX software development).

Jörn Walterمشاهده پروفایل

استاد

• Epigenetics
• Genetics
• Epigenomics
• +۵ مورد دیگر

Prof. Dr. Jörn Walter serves as a Senior Professor for Genetics and Epigenetics at Saarland University's Faculty of Natural Sciences and Technology. His laboratory investigates epigenetic mechanisms across development and disease states, with particular emphasis on DNA methylation, chromatin dynamics, and epigenomic mapping of cell types. Member of the International Human Epigenome Consortium (IHEC) Coordinator of the German Epigenome Program Director of an in-house Sequencing Facility (HiSeq2500, Mi-Seq, Nextseq-500) Research focuses include: Epigenetic programming during cellular differentiation DNA methylation dynamics in disease contexts Stem cell epigenetics and reprogramming Evolution of epigenetic mechanisms Recent publications highlight interdisciplinary approaches combining next-generation sequencing , bioinformatic modeling , and clinical epigenetics , with particular attention to immune cell development , metabolic disease epigenetics , and computational epigenomics . The group maintains collaborations with the West German Sequencing Center and contributes to epigenetic data standardization efforts. Lab members include active researchers like Dr. Nina Gasparoni , Dr. Gilles Gasparoni , and M.Sc. Alea Leismann , alongside an extensive alumni network of former advisees who have advanced epigenetic research in various institutions.

• Neurodegenerative Diseases
• Protein Aggregation
• Neuroinflammation
• +۷ مورد دیگر

Prof. Dr. Karin Danzer is a Group Leader at the Department of Neurology, Ulm University, and affiliated with the German Center for Neurodegenerative Diseases (DZNE). Her research investigates pathomechanisms in neurodegenerative disorders—particularly ALS and Parkinson's disease—focusing on protein aggregation (alpha-synuclein, TDP-43), neuroinflammation, and epigenetic regulation. She employs multi-omic single-cell sequencing, spatial transcriptomics, and in vivo models to study disease progression, vulnerability of neural cell populations, and therapeutic interventions. Research Focus: Her work spans (1) Prion-like propagation of misfolded proteins, (2) Aging-trauma interactions in neurodegeneration, (3) Heat-shock-protein chaperone systems, (4) Viral-infection triggers for ALS, (5) Neuroimmune dysregulation, and (6) Epigenetic biomarkers in blood/brain tissue. She develops novel TDP-43 mouse models for real-time tracking of protein aggregation. Team & Collaborations: Leads a team of 10+ researchers investigating molecular pathways through integrated wet-lab/bioinformatics approaches. Key projects include CRC 1506 'Aging at Interfaces' and CRC 1149 'Danger Response after Trauma'. Biomarker Development: Validates Contactin-associated protein-like 4 (CNTNAP4) for major depressive disorder and neurofilament light chain for ALS prognostics.

Mhaned Oubounytمشاهده پروفایل

پژوهشگر

• Single-cell transcriptomics
• Spatial single-cell network analysis
• Gene regulatory networks
• +۳ مورد دیگر

Dr. Mhaned Oubounyt is a Postdoctoral Researcher at the University of Hamburg, affiliated with the Computational Systems Biology (CoSy.Bio) group within the Faculty of Mathematics, Informatics and Natural Sciences. His work focuses on developing computational methods for analyzing single-cell and spatial transcriptomics data, particularly in the context of disease mechanisms and drug repurposing. He is actively involved in the NetMap project, advancing dimensionality reduction techniques using differential regulatory networks. Research interests include gene co-expression networks, spatial single-cell analysis, and systems medicine applications. His methodologies bridge computational biology with clinical and agricultural challenges, such as vaccine responses in pregnancy, plant disease resistance, and cardiovascular pathophysiology. Key contributions include the SCANet and Drugst platforms for drug candidate identification and network-based analysis. Publications highlight a strong focus on network biology applications across domains: from immune system modeling to plant stress responses, leveraging single-cell multi-omics integration. His work emphasizes translational research, with implications for personalized medicine and crop improvement. Collaborations span academic and clinical institutions, reflecting his interdisciplinary approach. Current projects aim to enhance predictive modeling of disease progression and therapeutic interventions through systems-level insights.

Simone Spulerمشاهده پروفایل

استاد

• Muscle Stem Cell Biology
• CRISPR/Cas9 and Base Editing
• Muscular Dystrophies
• +۳ مورد دیگر

Prof. Dr. Simone Spuler is a leading researcher in muscle stem cell biology and gene therapy at the Experimental and Clinical Research Center (ECRC) in Berlin, jointly affiliated with Charité - Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine. She serves as Director of the University Outpatient Clinic for Muscle Diseases, focusing on translational approaches for genetic and age-related muscle disorders. Develops CRISPR/Cas9 and base editing therapies for muscular dystrophies (LGMD2A, Dysferlinopathy) Translates stem cell research into clinical trials like MuST and BASKet Validates GMP-compliant manufacturing of primary human satellite cells (PHSats) for ATMP applications Her research interests center on muscle stem cell heterogeneity, regenerative medicine, and epigenetic mechanisms in critical illness myopathy. Recent work explores: CRISPR editing of patient-derived stem cells Humanized mouse models for dystrophy validation Epigenetic reprogramming in ICU-acquired weakness Decellularization protocols for diaphragm repair She leads a multidisciplinary team working on: Genome editing of CAPN3, LMNA, and Dysferlin mutations Stem cell expansion using bacterial nanocellulose Development of regenerative therapies for urinary incontinence Scientific awards include: Science4Life Venture Cup 2019 (Pharma Category) NLSInvest Award 2022 Einstein Visiting Fellowship (2019-2022) Her clinical and entrepreneurial efforts involve founding the startup MyoPax , which develops stem cell therapies for incurable muscle diseases, supported by grants from the German Federal Ministry of Education and Research (BMBF) and Else Kröner-Fresenius Foundation (EKFS). The MuST clinical trial for epispadias patients is funded with €4.3M. Her team collaborates with patient organizations like Coalition to Cure Calpain 3 and Deutsche Gesellschaft für Muskelkranke .

Florian Sicklingerمشاهده پروفایل

پزشک-پژوهشگر

• Immunocardiology
• Cardiac inflammation
• Cardiac fibrosis
• +۴ مورد دیگر

Dr. Florian Sicklinger is a Physician-Scientist and Assistant Doctor in the Department of Cardiology, Angiology and Pulmonology at Heidelberg University Hospital. He has been working at the Medical Clinic of Heidelberg University Hospital since 2021 and has been a Physician-Scientist in the Immunocardiology Research Group under Prof. Dr. med. Florian Leuschner since 2022. Education Medical studies at Heidelberg University (2013-2020) Doctorate at Heidelberg University Hospital (2016-2022), supervised by Prof. Dr. med. Florian Leuschner Research Interests Dr. Sicklinger's research focuses on the role of the immune system in ischemic heart disease and heart valve diseases, as well as the therapeutic modulation of cardiac inflammation and fibrosis. His work bridges clinical cardiology with immunological mechanisms to develop novel therapeutic approaches for cardiac conditions. He has published extensively on immune cell interactions following myocardial infarction, including studies on basophils, endothelial cells, and macrophages. Publication Trends Dr. Sicklinger's publications demonstrate a strong focus on the intersection of immunology and cardiology, with a clear progression toward increasingly sophisticated methodologies. His early work established standardized approaches for cardiac research models, while his more recent publications employ cutting-edge techniques like single-cell transcriptomics and high-throughput screening. His research consistently addresses the immune mechanisms underlying cardiac injury and repair processes across multiple model systems from mice to pigs. Awards and Recognition Postdoc Start-up Grant from the German Center for Cardiovascular Research (2022-2023) DZHK Paper of the Month (2021 and 2020) Otto-Hess Doctoral Scholarship from the German Cardiac Society (2017-2018) Scholarship from the German National Academic Foundation (2013-2020) Research Leadership As a key member of the Immunocardiology Research Group at Heidelberg University Hospital, Dr. Sicklinger has contributed significantly to developing novel methodologies for cardiac research, including minimal-invasive techniques for inducing myocardial infarction and high-throughput echocardiography-guided approaches. His work on immune cell dynamics after cardiac injury has provided important insights into potential therapeutic targets for improving cardiac recovery following myocardial infarction.

Priscilla A. Furthمشاهده پروفایل

استاد

• Bioinformatics
• Breast Cancer
• Estrogen Signaling
• +۴ مورد دیگر

Priscilla A. Furth is a Professor at Georgetown University's Department of Oncology and Medicine, with a distinguished career in disease pathophysiology and cancer research. She serves as an Anna Boyksen Fellow at the Technical University of Munich Institute for Advanced Study (TUM-IAS) since 2023, focusing on experimental bioinformatics and gender diversity in science. M.D. from Yale University (1979) Associate Dean for Faculty Development at Georgetown (2013–2021) Her research integrates bioinformatics and gene-regulatory mechanisms to analyze estrogen signaling pathways in breast cancer risk across diverse gender expressions. She pioneered investigations into circular RNA (circRNA) roles as biomarkers and explores their modification through anti-hormonal therapies. Current article trends show interdisciplinary work bridging quantum computing with network medicine , while maintaining focus on hormonal cancer mechanisms and vaccine immunology . Her 2024 publications emphasize multi-omics data integration and gender-inclusive oncology . Scientific recognition includes: 2023 Anna Boyksen Fellowship 2021 Women in Pathology Spotlight 2020 Excellence in Mentorship Award 2010 Georgetown Women in Medicine Award As Associate Dean, she developed faculty growth programs and continues mentoring through her TUM-IAS fellowship collaborations.